Treatment of Unresectable Stage III/IV or Recurrent Endometrial Carcinoma with Non-MMRd Tumour and Rapidly Growing or Symptomatic Disease
Clinical Scenario
Patients with unresectable stage III or IV endometrial carcinoma, or with recurrent disease, whose tumours are non-mismatch-repair deficient (non-MMRd), presenting with rapidly growing or symptomatic disease, who have not received prior chemotherapy in the advanced or recurrent setting (adjuvant chemotherapy excepted).
Treatment Approach
For immune checkpoint inhibitor-naive patients with non-MMRd tumours in this setting, immune checkpoint inhibitor-based therapy is a central component of the evidence-based approach. Additional options — including considerations based on specific tumour characteristics — are outlined in the full structured protocol.
References
DOI: 10.1016/S1470-2045(25)00167-6
- Patients with non-MMRd tumours with rapidly growing or symptomatic disease should be offered carboplatin–paclitaxel chemotherapy (I, A).
- Immune checkpoint inhibitor-naive patients with non-MMRd tumours should be offered pembrolizumab and lenvatinib (I, A).
View source ↗